scholarly journals Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis

2015 ◽  
pp. 2495 ◽  
Author(s):  
Afisi S Ismaila ◽  
Eline Huisman ◽  
Yogesh Punekar ◽  
Andreas Karabis
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Comparative Efficacy ◽  
Muscarinic Antagonist ◽  
Long Acting

scholarly journals Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis

Respirology ◽  
2015 ◽  
Vol 20 (8) ◽  
pp. 1153-1159 ◽  
Author(s):  
Nobuyuki Horita ◽  
Naoki Miyazawa ◽  
Koji Tomaru ◽  
Miyo Inoue ◽  
Takeshi Kaneko
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Beta Agonist ◽  
Inhaled Corticosteroid ◽  
Muscarinic Antagonist ◽  
Long Acting

scholarly journals Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy

BMJ Open ◽  
2013 ◽  
Vol 3 (3) ◽  
pp. e002312 ◽  
Author(s):  
Salima Punja ◽  
Liliane Zorzela ◽  
Lisa Hartling ◽  
Liana Urichuk ◽  
Sunita Vohra
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Comparative Efficacy ◽  
Short Acting ◽  
Long Acting

scholarly journals Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis

2016 ◽  
Vol 10 (2) ◽  
pp. 89-104 ◽  
Author(s):  
Max Schlueter ◽  
N Gonzalez-Rojas ◽  
Michael Baldwin ◽  
Lars Groenke ◽  
Florian Voss ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Fixed Dose ◽  
Muscarinic Antagonists ◽  
Comparative Efficacy ◽  
Long Acting ◽  
Β2 Agonists

scholarly journals Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Akira Koarai ◽  
Mitsuhiro Yamada ◽  
Tomohiro Ichikawa ◽  
Naoya Fujino ◽  
Tomotaka Kawayama ◽  
...  
Keyword(s):  
Systematic Review ◽  
Combination Therapy ◽  
Triple Therapy ◽  
Odds Ratio ◽  
Controlled Trial ◽  
Meta Analysis ◽  
Beta Agonist ◽  
History Of ◽  
Dyspnea Score ◽  
Long Acting

Abstract Background Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been recommended for patients with COPD who have severe symptoms and a history of exacerbations because it reduces the exacerbations. In addition, a reducing effect on mortality has been shown by this treatment. However, the evidence is mainly based on one large randomized controlled trial IMPACT study, and it remains unclear whether the ICS add-on treatment is beneficial or not. Recently, a large new ETHOS trial has been performed to clarify the ICS add-on effects. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety including ETHOS trial. Methods We searched relevant randomized control trials (RCTs) and analyzed the exacerbations, quality of life (QOL), dyspnea symptom, lung function and adverse events including pneumonia and mortality, as the outcomes of interest. Results We identified a total of 6 RCTs in ICS add-on protocol (N = 13,579). ICS/LAMA/LABA treatment (triple therapy) significantly decreased the incidence of exacerbations (rate ratio 0.73, 95% CI 0.64–0.83) and improved the QOL score and trough FEV1 compared to LAMA/LABA. In addition, triple therapy significantly improved the dyspnea score (mean difference 0.33, 95% CI 0.18–0.48) and mortality (odds ratio 0.66, 95% CI 0.50–0.87). However, triple therapy showed a significantly higher incidence of pneumonia (odds ratio 1.52, 95% CI 1.16–2.00). In the ICS-withdrawal protocol including 2 RCTs, triple therapy also showed a significantly better QOL score and higher trough FEV1 than LAMA/LABA. Concerning the trough FEV1, QOL score and dyspnea score in both protocols, the differences were less than the minimal clinically important difference. Conclusion Triple therapy causes a higher incidence of pneumonia but is a more preferable treatment than LAMA/LABA due to the lower incidence of exacerbations, higher trough FEV1 and better QOL score. In addition, triple therapy is also superior to LABA/LAMA due to the lower mortality and better dyspnea score. However, these results should be only applied to patients with symptomatic moderate to severe COPD and a history of exacerbations. Clinical Trial Registration: PROSPERO; CRD42020191978.

Sign in / Sign up

Export Citation Format

Share Document